Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke.
Level II
Where this comes from
- Record sourced from PubMed, PMID 21737808.
- Also identified by DOI 10.1161/STROKEAHA.111.618215 and PMC identifier 3181080.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.
Medical subject headings
- Anti-Bacterial Agents
- Brain Ischemia
- Matrix Metalloproteinase 9
- Minocycline
- Stroke